Hester Biosciences Limited (IN:HESTERBIO)
:HESTERBIO
Want to see IN:HESTERBIO full AI Analyst Report?
HESTERBIO Stock Chart & Stats
₹1605.75
-₹5.75(-0.24%)
At close: 4:00 PM EST
₹1605.75
-₹5.75(-0.24%)
Day’s Range― - ―
52-Week Range₹1,250.95 - ₹2,347.70
Previous CloseN/A
Volume2.45K
Average Volume (3M)308.00
Market Cap
₹15.65B
Enterprise Value₹17.89B
Total Cash (Recent Filing)₹281.58M
Total Debt (Recent Filing)₹2.14B
Price to Earnings (P/E)18.6
Beta0.56
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)52.41
Shares Outstanding8,506,865
10 Day Avg. Volume428
30 Day Avg. Volume308
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.88
Price to Sales (P/S)3.12
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Re-accelerationA clear re-acceleration in revenue signals improved market traction and demand for core veterinary vaccines. Sustained top-line growth over multiple years supports scale economies, steadier cash generation and the ability to invest in capacity and R&D, strengthening long-term competitiveness.
Improved ProfitabilityRestored net margins around mid-teens indicate better cost control, pricing power or higher-margin product mix. Durable improvement in profitability enhances free cash flow potential, funds reinvestment without reliance on external financing, and bolsters resilience through industry cycles.
Strengthening Balance SheetMaterial reduction in leverage improves financial flexibility and lowers solvency risk. A de-leveraging trend increases room for strategic investment, reduces interest expense exposure and better positions the company to withstand profit volatility or pursue targeted M&A in the animal-health space.
Bears Say
Cash Flow VolatilityA history of deeply negative free cash flow creates execution risk: intermittent cash shortages can constrain capex, working capital and dividend policy. Even with recent improvement, inconsistent conversion of profits to cash raises funding and operational risk over multi-quarter horizons.
Inconsistent Earnings QualityPronounced margin volatility reduces predictability of profit streams and complicates planning. For a specialty drug/vaccine maker, swings imply sensitivity to input costs, product mix or pricing; this undermines confidence in sustained margin levels and steady return generation.
Still-Sizable Absolute DebtAlthough debt ratios have improved, meaningful absolute debt can limit strategic flexibility and raise fixed costs. In a downturn or margin setback, servicing that debt could pressure cash flow, constrain growth investments and force tougher liquidity choices over several quarters.
Hester Biosciences Limited News
HESTERBIO FAQ
What was Hester Biosciences Limited’s price range in the past 12 months?
Hester Biosciences Limited lowest stock price was ₹1250.95 and its highest was ₹2347.70 in the past 12 months.
What is Hester Biosciences Limited’s market cap?
Hester Biosciences Limited’s market cap is ₹15.65B.
When is Hester Biosciences Limited’s upcoming earnings report date?
Hester Biosciences Limited’s upcoming earnings report date is Aug 12, 2026 which is in 82 days.
How were Hester Biosciences Limited’s earnings last quarter?
Hester Biosciences Limited released its earnings results on May 15, 2026. The company reported ₹19.45 earnings per share for the quarter, beating the consensus estimate of N/A by ₹19.45.
Is Hester Biosciences Limited overvalued?
According to Wall Street analysts Hester Biosciences Limited’s price is currently Overvalued.
Does Hester Biosciences Limited pay dividends?
Hester Biosciences Limited pays a Annually dividend of ₹7 which represents an annual dividend yield of 0.44%. See more information on Hester Biosciences Limited dividends here
What is Hester Biosciences Limited’s EPS estimate?
Hester Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hester Biosciences Limited have?
Hester Biosciences Limited has 8,506,865 shares outstanding.
What happened to Hester Biosciences Limited’s price movement after its last earnings report?
Hester Biosciences Limited reported an EPS of ₹19.45 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.669%.
Which hedge fund is a major shareholder of Hester Biosciences Limited?
Currently, no hedge funds are holding shares in IN:HESTERBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hester Biosciences Limited
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates in two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for diseases, such as newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reo, marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, avian encephalomyelitis, etc. It also offers vaccines for large animals comprising Goat Pox, Peste des Petits Ruminants, Brucellosis, Mastitis, Metritis, and various infectious diseases, as well as infections, reproductive disorders, theileriosis, parasitic diseases, etc. In addition, the company provides feed supplements, such as toxin binder, trace minerals, enzyme preparation, and bypass fat; disinfectants for farms and equipment, and water sanitizers; nutrition products consisting of mineral mixtures, fertility supplements, and growth tonics; and herbal products, including growth promoters, herbal replacers for choline chloride, stress relievers and immunity boosters, respiratory stimulants, liver tonics, wound healing preparations, uterine tonics, digestive tonics and anti-bloat solutions, ectoparasiticide preparations, anti-mastitis, and anti-prolapse preparations. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India.
Technical Analysis
Gufic Biosciences Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
―
Unichem Laboratories Limited
―